Literature DB >> 34812907

Connective Tissue Growth Factor Single Nucleotide Polymorphisms in (Familial) Pulmonary Fibrosis and Connective Tissue Disease Associated Interstitial Lung Disease.

Dymph Klay1, Joanne J van der Vis1,2, Suzan M Roothaan3, Tri Q Nguyen3, Jan C Grutters1,4, Roel Goldschmeding3, Coline H M van Moorsel5,6.   

Abstract

PURPOSE: Connective tissue growth factor (CTGF) is an important mediator in fibrotic disease. Single nucleotide polymorphisms (SNPs) in CTGF have been found to be associated with different fibrotic diseases and CTGF protein was found to be upregulated in lung tissue, bronchoalveolar lavage cells, and plasma of idiopathic pulmonary fibrosis (IPF) patients. We investigated whether genetic variants predispose to sporadic IPF (spIPF), familial pulmonary fibrosis (FPF), and connective tissue disease associated ILD (CTD-ILD).
METHODS: In total, 294 patients with spIPF and 294 healthy individuals were genotyped for CTGF rs12526196, rs9402373, rs6918698, and rs9399005. For replication of CTGF rs6918698 findings in pulmonary fibrosis, 128 patients with FPF, 125 with CTD-ILD, and an independent control cohort of 130 individuals were included. Lung tissue of 6 IPF patients was stained for CTGF to assess pulmonary localization.
RESULTS: Of the four SNPs, only the minor allele frequency (MAF) of CTGF rs6918698 deviated between spIPF (MAF 0.41) and controls (MAF 0.47; OR 0.774 (0.615-0.975); p = 0.030). Further comparison of CTGF rs6918698G showed a difference between FPF (MAF 0.33) and controls (MAF 0.48; OR 0.545 (0.382-0.778); p = 0.001), but not with CTD-ILD. CTGF was localized in alveolar and bronchiolar epithelium, alveolar macrophages, myofibroblasts and endothelium and highly expressed in the basal cell layer of sandwich foci.
CONCLUSION: CTGF rs6918698G associates with spIPF and with FPF, but not with CTD-ILD in a Dutch cohort. CTGF is localized in lung tissue involved in IPF pathogenesis. Further research into the role of this SNP on CTGF expression and fibrogenesis is warranted.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Connective tissue disease associated interstitial lung disease; Connective tissue growth factor; Familial pulmonary fibrosis; Idiopathic pulmonary fibrosis; Single nucleotide polymorphism

Mesh:

Substances:

Year:  2021        PMID: 34812907     DOI: 10.1007/s00408-021-00494-y

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  43 in total

1.  Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Collaborating Centers.

Authors:  K B Baumgartner; J M Samet; D B Coultas; C A Stidley; W C Hunt; T V Colby; J A Waldron
Journal:  Am J Epidemiol       Date:  2000-08-15       Impact factor: 4.897

2.  The genetic basis of idiopathic pulmonary fibrosis.

Authors:  Jonathan A Kropski; Timothy S Blackwell; James E Loyd
Journal:  Eur Respir J       Date:  2015-04-02       Impact factor: 16.671

3.  Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis.

Authors:  Pierre-Antoine Juge; Raphaël Borie; Caroline Kannengiesser; Steven Gazal; Patrick Revy; Lidwine Wemeau-Stervinou; Marie-Pierre Debray; Sébastien Ottaviani; Sylvain Marchand-Adam; Nadia Nathan; Gabriel Thabut; Christophe Richez; Hilario Nunes; Isabelle Callebaut; Aurélien Justet; Nicolas Leulliot; Amélie Bonnefond; David Salgado; Pascal Richette; Jean-Pierre Desvignes; Huguette Lioté; Philippe Froguel; Yannick Allanore; Olivier Sand; Claire Dromer; René-Marc Flipo; Annick Clément; Christophe Béroud; Jean Sibilia; Baptiste Coustet; Vincent Cottin; Marie-Christophe Boissier; Benoit Wallaert; Thierry Schaeverbeke; Florence Dastot le Moal; Aline Frazier; Christelle Ménard; Martin Soubrier; Nathalie Saidenberg; Dominique Valeyre; Serge Amselem; Catherine Boileau; Bruno Crestani; Philippe Dieudé
Journal:  Eur Respir J       Date:  2017-05-11       Impact factor: 16.671

4.  Effect of Muc5b promoter polymorphism on disease predisposition and survival in idiopathic interstitial pneumonias.

Authors:  Joanne J van der Vis; Reinier Snetselaar; Karin M Kazemier; Liesbeth ten Klooster; Jan C Grutters; Coline H M van Moorsel
Journal:  Respirology       Date:  2015-12-24       Impact factor: 6.424

5.  A common MUC5B promoter polymorphism and pulmonary fibrosis.

Authors:  Max A Seibold; Anastasia L Wise; Marcy C Speer; Mark P Steele; Kevin K Brown; James E Loyd; Tasha E Fingerlin; Weiming Zhang; Gunnar Gudmundsson; Steve D Groshong; Christopher M Evans; Stavros Garantziotis; Kenneth B Adler; Burton F Dickey; Roland M du Bois; Ivana V Yang; Aretha Herron; Dolly Kervitsky; Janet L Talbert; Cheryl Markin; Joungjoa Park; Anne L Crews; Susan H Slifer; Scott Auerbach; Michelle G Roy; Jia Lin; Corinne E Hennessy; Marvin I Schwarz; David A Schwartz
Journal:  N Engl J Med       Date:  2011-04-21       Impact factor: 91.245

6.  MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease.

Authors:  Pierre-Antoine Juge; Joyce S Lee; Esther Ebstein; Hiroshi Furukawa; Evgenia Dobrinskikh; Steven Gazal; Caroline Kannengiesser; Sébastien Ottaviani; Shomi Oka; Shigeto Tohma; Naoyuki Tsuchiya; Jorge Rojas-Serrano; Montserrat I González-Pérez; Mayra Mejía; Ivette Buendía-Roldán; Ramcés Falfán-Valencia; Enrique Ambrocio-Ortiz; Effrosyni Manali; Spyros A Papiris; Theofanis Karageorgas; Dimitrios Boumpas; Katarina Antoniou; Coline H M van Moorsel; Joanne van der Vis; Yaël A de Man; Jan C Grutters; Yaping Wang; Raphaël Borie; Lidwine Wemeau-Stervinou; Benoît Wallaert; René-Marc Flipo; Hilario Nunes; Dominique Valeyre; Nathalie Saidenberg-Kermanac'h; Marie-Christophe Boissier; Sylvain Marchand-Adam; Aline Frazier; Pascal Richette; Yannick Allanore; Jean Sibilia; Claire Dromer; Christophe Richez; Thierry Schaeverbeke; Huguette Lioté; Gabriel Thabut; Nadia Nathan; Serge Amselem; Martin Soubrier; Vincent Cottin; Annick Clément; Kevin Deane; Avram D Walts; Tasha Fingerlin; Aryeh Fischer; Jay H Ryu; Eric L Matteson; Timothy B Niewold; Deborah Assayag; Andrew Gross; Paul Wolters; Marvin I Schwarz; Michael Holers; Joshua J Solomon; Tracy Doyle; Ivan O Rosas; Cornelis Blauwendraat; Mike A Nalls; Marie-Pierre Debray; Catherine Boileau; Bruno Crestani; David A Schwartz; Philippe Dieudé
Journal:  N Engl J Med       Date:  2018-10-20       Impact factor: 91.245

7.  An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.

Authors:  William D Travis; Ulrich Costabel; David M Hansell; Talmadge E King; David A Lynch; Andrew G Nicholson; Christopher J Ryerson; Jay H Ryu; Moisés Selman; Athol U Wells; Jurgen Behr; Demosthenes Bouros; Kevin K Brown; Thomas V Colby; Harold R Collard; Carlos Robalo Cordeiro; Vincent Cottin; Bruno Crestani; Marjolein Drent; Rosalind F Dudden; Jim Egan; Kevin Flaherty; Cory Hogaboam; Yoshikazu Inoue; Takeshi Johkoh; Dong Soon Kim; Masanori Kitaichi; James Loyd; Fernando J Martinez; Jeffrey Myers; Shandra Protzko; Ganesh Raghu; Luca Richeldi; Nicola Sverzellati; Jeffrey Swigris; Dominique Valeyre
Journal:  Am J Respir Crit Care Med       Date:  2013-09-15       Impact factor: 21.405

8.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

9.  Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry.

Authors:  Jaana Kaunisto; Eija-Riitta Salomaa; Ulla Hodgson; Riitta Kaarteenaho; Hannu Kankaanranta; Katri Koli; Tero Vahlberg; Marjukka Myllärniemi
Journal:  ERJ Open Res       Date:  2019-07-08

10.  Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK.

Authors:  Helen Strongman; Imran Kausar; Toby M Maher
Journal:  Adv Ther       Date:  2018-04-11       Impact factor: 3.845

View more
  2 in total

1.  Interference with connective tissue growth factor attenuated fibroblast-to-myofibroblast transition and pulmonary fibrosis.

Authors:  Zhizhou Yang; Mengmeng Wang; Liping Cao; Rui Liu; Yi Ren; Liang Li; Yuhao Zhang; Chao Liu; Wei Zhang; Shinan Nie; Zhaorui Sun
Journal:  Ann Transl Med       Date:  2022-05

2.  LUNG Year in Review: 2021.

Authors:  Peter V Dicpinigaitis
Journal:  Lung       Date:  2022-01-18       Impact factor: 3.777

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.